ISPOR CEO Rob Abbott Advocates for HEOR in Global Healthcare Decision Making

By HEOR Staff Writer

November 9, 2023

Understanding the Importance and Scope of HEOR in Today’s Healthcare Landscape

The Professional Society for Health Economics and Outcomes Research (ISPOR) is a global non-profit organisation. It promotes the use of health economics and outcomes research (HEOR) in medical care decision-making. Recently, CEO Rob Abbott discussed the organisation’s objective, the importance of HEOR, and the future of healthcare. 

ISPOR’s membership is comprised of individuals from academia, industry, patient groups, and payers. These individuals come from 110 different countries. This organisation’s work would not be possible without its broad membership. This guides debates and conversations by offering a variety of perspectives.

 Abbott stressed the crucial role of HEOR in today’s world, particularly in overburdened healthcare systems. HEOR offers valuable data and insights, aiding tough decisions in the healthcare sector. It helps achieve superior results at lower costs.

In addition, Abbott clarified the differences between HEOR and health technology assessment (HTA). Compared to HEOR, which includes a wider field of research and incorporates notions such as real-world evidence, real-world data, and patient participation, HTA primarily concentrates on the effectiveness of a particular technology.

The CEO also discussed the potential and difficulties that will exist in the healthcare industry in the year 2030. Some of these problems and opportunities include the concept of whole health, as well as affordability and sustainability. He stressed the significance of scientific rigor and evidence in the process of guiding decisions and policies pertaining to healthcare.

ISPOR’s Role in Emerging Markets and the Incorporation of Patient Perspectives in Healthcare

The function of ISPOR in developing markets was on the table. These markets are experiencing an acute shortage of practicable health economic models. ISPOR has regional chapters in over one hundred countries. The majority of which are either economies in transition or countries with low or middle incomes. The organisation is providing substantial assistance in the form of active support for the development of HEOR capacity and its use in these regions.

Lastly, Abbott discussed the significance of incorporating the viewpoints and preferences of patients into the decision-making processes that take place inside the healthcare system. ISPOR has long been dedicated to achieving this objective. In order to ensure that the patient voice is heard, the organisation has formed patient roundtables and a special interest group.

Global Healthcare Decision Making

Abbott concluded his speech by emphasising ISPOR’s dedication to incorporating HEOR into decision-making. Their goal is to improve health outcomes at a more affordable cost. He invited anyone interested in HEOR or enhancing the accessibility, equity, and impact of healthcare systems on patients, to join ISPOR. 

Reference url

Recent Posts

Paving the Way for Digital Health Technologies: NICE’s Bold New Strategy for the NHS

By HEOR Staff Writer

October 9, 2025

The National Institute for Health and Care Excellence (NICE) is expanding its technology appraisals programme, and starting April 2026, this will include digital health technologies that are placed on an equal legal footing with medicines in the NHS. This initiative forms part of the NHS 10-year ...
Health Misinformation Autism: The Dangers of Politicized Science in Vaccine and Drug Discourse

By João L. Carapinha

October 7, 2025

The BMJ article “Tylenol, vaccines, and autism: the medical mayhem of the MAGA methodologists” argues that political and ideological actors, notably aligned with the MAGA movement, are promoting health misinformation about autism, vaccines, and paracetamol. They amplify preliminary, misinterprete...
Lurbinectedin SCLC Therapy: FDA Approval and Its Economic Implications

By João L. Carapinha

October 6, 2025

The U.S. Food and Drug Administration (FDA) has recently approved lurbinectedin SCLC therapy in combination with atezolizumab, or with atezolizumab and hyaluronidase-qvfc, for the treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC). This regulatory decision reflects ...